

**Table 12. Budget impact for four months panitumumab as third line treatment**

	<b>30 patients</b>	<b>50 patients</b>
Comparator: trifluridine-tipiracil (Lonsurf <sup>®</sup> ) with bevacizumab		
Panitumumab total medicines acquisition cost*	¶¶¶	¶¶¶
Trifluridine-tipiracil (Lonsurf <sup>®</sup> ) <sup>†</sup> with bevacizumab <sup>§</sup> total medicines acquisition cost	¶¶¶	¶¶¶
<b>Overall net cost</b>	<b>¶¶¶ Cost saving</b>	<b>¶¶¶ Cost saving</b>
Costs exclude VAT Average adult weight 79 kg <sup>30</sup> Mean body surface area 1.79 m <sup>2</sup> [40] *6 mg/kg IV infusion every 2 weeks <sup>1</sup> †35 mg/m <sup>2</sup> /dose twice daily on days 1-5 and 8-12 <sup>38</sup> §5 mg/kg IV infusion every 2 weeks <sup>39</sup> ¶¶¶ commercial in confidence figure removed		